Genus/£GNS

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Genus

Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.

Ticker

£GNS

Primary listing

LSE

Industry

Biotechnology

Employees

3,500

ISIN

GB0002074580

Genus Metrics

BasicAdvanced
£1.4B
-
-£0.06
0.48
£0.32
1.45%

What the Analysts think about Genus

Analyst ratings (Buy, Hold, Sell) for Genus stock.

Bulls say / Bears say

Genus achieved a 16% increase in revenue to £689.7 million in 2023, indicating strong demand for its products. (businesswire.com)
The company reported a 10% rise in adjusted operating profit, reflecting effective cost management and operational efficiency. (businesswire.com)
Genus's PRRS-resistant pig program is progressing well, with favorable regulatory decisions in Brazil and Colombia, and ongoing discussions with the US FDA, positioning the company for future growth. (businesswire.com)
Net income declined by 19% to £33.3 million in 2023, indicating potential profitability challenges. (simplywall.st)
The profit margin decreased from 6.9% to 4.8%, suggesting increased costs or pricing pressures. (simplywall.st)
PIC China's operating profit decreased by 60% due to market difficulties and supply chain investments, highlighting regional vulnerabilities. (businesswire.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Genus Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Genus Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £GNS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs